x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DAB-0012429
| Product Information | |
|---|---|
| Clonality | Monoclonal |
| Isotype | IgG |
| Host Species | Rabbit |
| Reactivity | Human, Mouse, Rat |
| Applications | WB |
| Product Description | Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues near the carboxy terminus of human PGK1 protein. |
| Format | Liquid |
| Purity | Affinity purity |
| Target Information | |
|---|---|
| Target Name | PGK1 |
| UniProt No. | P00558 |
| Gene ID | 5230 |
| Gene Description | PGK1 is an essential enzyme in the glycolysis pathway. It catalyzes the reversible phospho-transfer reaction from 1, 3-diphosphoglycerate to ADP to form ATP and 3-phosphoglycerate. The expression of PGK1 is upregulated in many cancer types and plays an important role in cancer cell proliferation and metastasis. PGK1 can also function as a protein kinase. ERK can phosphorylate PGK1 at Ser203. This phosphorylation changes PGK1 conformation and leads to its translocation from cytoplasm to mitochondria. There it interacts and phosphorylates PDHK1, which leads to PDHK1 inhibition, blocks pyruvate to coenzyme A conversion, and promotes cytosolic lactate concentration. Acetylated PGK1 can phosphorylate Beclin1 to induce autophagy. PGK1 is activated by autophosphorylation at Tyr324. PTEN can dephosphorylate PGK1 at this site to downregulate its activity. In cancer cells, loss of PTEN enhances PGK1 activity and promotes glycolysis and tumor growth. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped at 4 °C. |
| Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
| Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/mL BSA, 50% glycerol, and less than 0.02% sodium azide. |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
